First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study
JY Douillard, G Ostoros, M Cobo, T Ciuleanu… - British journal of …, 2014 - nature.com
… gefitinib follow-up measure study reported here is, to our knowledge, the first prospective,
large-scale study of first-line gefitinib … Our study demonstrates that first-line gefitinib is effective …
large-scale study of first-line gefitinib … Our study demonstrates that first-line gefitinib is effective …
… gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
K Park, EH Tan, K O'Byrne, L Zhang, M Boyer… - The Lancet …, 2016 - thelancet.com
… gefitinib are approved for first-line treatment of EGFR mutation-positive non-small-cell lung
cancer (NSCLC). We aimed to compare the efficacy and safety of afatinib and gefitinib in this …
cancer (NSCLC). We aimed to compare the efficacy and safety of afatinib and gefitinib in this …
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically …
M Fukuoka, YL Wu, S Thongprasert… - Journal of clinical …, 2011 - ascopubs.org
… , indicating that in the first-line setting, gefitinib should not be … of previous first-line, single-arm
studies of gefitinib in patients … 24,33 comparing first-line gefitinib with doublet chemotherapy…
studies of gefitinib in patients … 24,33 comparing first-line gefitinib with doublet chemotherapy…
… versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
YL Wu, Y Cheng, X Zhou, KH Lee, K Nakagawa… - The Lancet …, 2017 - thelancet.com
Background Dacomitinib is a second-generation, irreversible EGFR tyrosine kinase inhibitor.
We compared its efficacy and safety with that of the reversible EGFR tyrosine kinase …
We compared its efficacy and safety with that of the reversible EGFR tyrosine kinase …
Phase III, randomized, open‐label, first‐line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non‐small‐cell lung …
YL WU, DT CHU, B Han, X Liu, L Zhang… - Asia‐Pacific Journal …, 2012 - Wiley Online Library
… first-line treatment of patients with mutation-negative tumors due to the comparatively poorer
outcome with gefitinib … Chinese subset of IPASS, first-line gefitinib prolonged PFS, increased …
outcome with gefitinib … Chinese subset of IPASS, first-line gefitinib prolonged PFS, increased …
Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with …
M Fukuoka, Y Wu, S Thongprasert, C Yang… - Journal of Clinical …, 2009 - ascopubs.org
8006^ Background: IPASS demonstrated overall superiority of first-line G vs C/P for
progression-free survival (PFS) in never/light ex-smokers with stage IIIB/IV adenocarcinoma NSCLC …
progression-free survival (PFS) in never/light ex-smokers with stage IIIB/IV adenocarcinoma NSCLC …
Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non …
T Cufer, E Vrdoljak, R Gaafar, I Erensoy… - Anti-cancer …, 2006 - journals.lww.com
… Our objective was to evaluate gefitinib (IRESSA), an epidermal growth factor receptor
tyrosine kinase inhibitor, versus docetaxel as second-line monotherapy for advanced non-small-…
tyrosine kinase inhibitor, versus docetaxel as second-line monotherapy for advanced non-small-…
… versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial.
T Mok, Y Cheng, X Zhou, KH Lee, K Nakagawa, S Niho… - 2017 - ascopubs.org
The full, final text of this abstract will be available at abstracts.asco.org at 7:30 AM (EDT) on
Monday, June 5, 2017, and in the Annual Meeting Proceedings online supplement to the …
Monday, June 5, 2017, and in the Annual Meeting Proceedings online supplement to the …
Phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in selected patients (pts) with advanced non-small cell lung cancer …
Y Ohe, Y Ichinose, Y Nishiwaki, N Yamamoto… - Journal of Clinical …, 2009 - ascopubs.org
8044^ Background: The IRESSA Pan Asia Study (IPASS) demonstrated superiority of G vs C/P
in 1,217 clinically selected chemonaïve pts in Asia with advanced NSCLC. PFS favored …
in 1,217 clinically selected chemonaïve pts in Asia with advanced NSCLC. PFS favored …
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib …
… of continuing gefitinib combined with chemotherapy versus chemotherapy alone in patients
with EGFR-mutation-positive advanced NSCLC with acquired resistance to first-line gefitinib. …
with EGFR-mutation-positive advanced NSCLC with acquired resistance to first-line gefitinib. …
相关搜索
- randomised open label first line treatment
- multicentre open label first line treatment
- first line gefitinib lung cancer
- first line gefitinib monotherapy
- first line gefitinib single arm study
- first line therapy
- egfr mutation first line treatment
- first line single agent
- first line dacomitinib
- first line tyrosine kinase inhibitors
- randomized open label study
- first line gefitinib somatic egfr mutations
- first line gefitinib indication for chemotherapy
- first line gefitinib nsclc patients
- first line gefitinib predictive marker
- first line gefitinib growth factor receptor